Bonnie Joe

Dr. Bonnie Joe

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Radiology
Verified
Journal Article
Closed access
SPSavannah Corrina Partridge
Savannah Corrina Partridge
ZZZheng Zhang
Zheng Zhang
DNDavid C. Newitt
David C. Newitt
JGJessica E. Gibbs
Jessica E. Gibbs
TCThomas L. Chenevert
Thomas L. Chenevert
FIFor the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators
For the ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators
Purpose To determine if the change in tumor apparent diffusion coefficient (ADC) at diffusion-weighted (DW) MRI is predictive of pathologic complete response (pCR) to neoadjuvant chemotherapy for breast cancer. Materials and Methods In this prospective multicenter study, 272 consecutive women with breast cancer were enrolled at 10 institutions (from August 2012 to January 2015) and were randomized to treatment with 12 weekly doses of paclitaxel (with or without an experimental agent), followed by 12 weeks of treatment with four cycles of anthracycline. Each woman underwent breast DW MRI before treatment, at early treatment (3 weeks), at midtreatment (12 weeks), and after treatment. Percentage change in tumor ADC from that before treatment (ΔADC) was measured at each time point. Performance for predicting pCR was assessed by using the area under the receiver operating characteristic curve (AUC) for the overall cohort and according to tumor hormone receptor (HR)/human epidermal growth factor receptor 2 (HER2) disease subtype. Results The final analysis included 242 patients with evaluable serial imaging data, with a mean age of 48 years ± 10 (standard deviation); 99 patients had HR-positive (hereafter, HR+)/HER2-negative (hereafter, HER2-) disease, 77 patients had HR-/HER2- disease, 42 patients had HR+/HER2+ disease, and 24 patients had HR-/HER2+ disease. Eighty (33%) of 242 patients experienced pCR. Overall, ΔADC was moderately predictive of pCR at midtreatment/12 weeks (AUC = 0.60; 95% confidence interval [CI]: 0.52, 0.68; P = .017) and after treatment (AUC = 0.61; 95% CI: 0.52, 0.69; P = .013). Across the four disease subtypes, midtreatment ΔADC was predictive only for HR+/HER2- tumors (AUC = 0.76; 95% CI: 0.62, 0.89; P < .001). In a test subset, a model combining tumor subtype and midtreatment ΔADC improved predictive performance (AUC = 0.72; 95% CI: 0.61, 0.83) over ΔADC alone (AUC = 0.57; 95% CI: 0.44, 0.70; P = .032.). Conclusion After 12 weeks of therapy, change in breast tumor apparent diffusion coefficient at MRI predicts complete pathologic response to neoadjuvant chemotherapy. © RSNA, 2018 Online supplemental material is available for this article.

1 March 2023 in Radiology
Verified
Journal Article
Closed access
MCMaggie Chung
Maggie Chung
ECEvan Calabrese
Evan Calabrese
JMJohn Mongan
John Mongan
KRKimberly M. Ray
Kimberly M. Ray
JHJessica H. Hayward
Jessica H. Hayward
ALAmie Y. Lee
Amie Y. Lee
Generating simulated contrast-enhanced breast MRI scans with use of deep learning was feasible, and simulated scans were judged to have a similar appearance to real contrast-enhanced MRI scans. Background There is increasing interest in noncontrast breast MRI alternatives for tumor visualization to increase the accessibility of breast MRI. Purpose To evaluate the feasibility and accuracy ...

1 August 2012 in Radiology
Verified
Journal Article
Closed access
VAVignesh A. Arasu
Vignesh A. Arasu
BJBonnie Joe
Bonnie Joe
NLNatalya M. Lvoff
Natalya M. Lvoff
JLJessica W.T. Leung
Jessica W.T. Leung
RBR. James Brenner
R. James Brenner
ESEdward A. Sickles
Edward A. Sickles
Following breast conservation therapy, asymptomatic recurrences are detected at a significantly earlier stage with semiannual ipsilateral surveillance mammography compared with noncompliant annual mammography. PurposeTo compare cancer recurrence outcomes on the basis of compliant semiannual versus noncompliant annual ipsilateral mammographic surveillance following breast conservation therapy (BCT).Materials and MethodsA HIPAA-compliant retrospective review was performed of post-BCT examinations from 1997 through 2008 by using a deidentified database. The Committee on Human Research did not require institutional review board approval for this study, which was considered quality assurance. Groups were classified according to compliance with institutional post-BCT protocol, which recommends semiannual mammographic examinations of the ipsilateral breast for 5 years. A compliant semiannual examination was defined as an examination with an interval of 0–9 months, although no examination had intervals less than 3 months. A noncompliant annual examination was defined as an examination with an interval of 9–18 months. Cancer recurrence outcomes were compared on the basis of the last examination interval leading to diagn...

1 May 2021 in Radiology: Imaging Cancer
Verified
Journal Article
Closed access
WTWendy Tu
Wendy Tu
DGDavid S. Gierada
David S. Gierada
BJBonnie Joe
Bonnie Joe

1 October 2016 in American Journal of Roentgenology
Verified
Journal Article
Closed access
JHJessica H. Hayward
Jessica H. Hayward
KRKimberly M. Ray
Kimberly M. Ray
DWDorota J. Wisner
Dorota J. Wisner
JKJohn Kornak
John Kornak
WLWeiwen Lin
Weiwen Lin
ESEdward A. Sickles
Edward A. Sickles
OBJECTIVE. The objective of the present study is to evaluate the effect of comparison with multiple prior mammograms on the outcomes of screening mammography relative to comparison with a single prior mammogram. MATERIALS AND METHODS. We retrospectively analyzed 46,288 consecutive screening mammograms performed at our institution for 22,792 women. We divided these examinations into three groups: those interpreted without comparison with prior mammograms, those interpreted in comparison with one prior examination, and those interpreted in comparison with two or more prior examinations. For each group, we determined the rate of examination recall. We also calculated the positive predictive value of recall (i.e., positive predictive value level 1 [PPV1]) and the cancer detection rate (CDR) for both the group of examinations compared with a single prior mammogram and the group compared with multiple prior mammograms. Generalized estimating equations with the logistic link function were used to determine the r...

17 November 2020 in Radiology
Verified
Journal Article
Closed access
EMElizabeth S. McDonald
Elizabeth S. McDonald
JRJustin Romanoff
Justin Romanoff
HRHabib Rahbar
Habib Rahbar
AKAveri E. Kitsch
Averi E. Kitsch
SHSara M. Harvey
Sara M. Harvey
SPSavannah Corrina Partridge
Savannah Corrina Partridge
An approach for measuring mean apparent diffusion coefficient that used two b values is sufficient for improving diagnostic performance of breast MRI and reducing the biopsy rate by up to 22.4% wit... Background The Eastern Cooperative Oncology Group and American College of Radiology Imaging Network Cancer Research Group A6702 multicenter trial helped confirm the potential of diffusion-weighted ...